A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor